Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/51852
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Treatment of scedosporiosis with Voriconazole: Clinical experience with 107 patients |
Author: | Troke, P. Aguirrebengoa, K. Arteaga, C. Ellis, D. Heath, C. Lutsar, I. Rovira, M. Nguyen, Q. Slavin, M. Chen, S. |
Citation: | Antimicrobial Agents and Chemotherapy, 2008; 52(5):1743-1750 |
Publisher: | Amer Soc Microbiology |
Issue Date: | 2008 |
ISSN: | 0066-4804 1098-6596 |
Statement of Responsibility: | Peter Troke, Koldo Aguirrebengoa, Carmen Arteaga, David Ellis, Christopher H. Heath, Irja Lutsar, Montserrat Rovira, Quoc Nguyen, Monica Slavin, and Sharon C. A. Chen |
Abstract: | The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% of patients had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), and surgery/trauma (15%) were the predominant underlying conditions. A successful therapeutic response was achieved in 57% of patients (median, 103 therapy days), with > 98% of those responding receiving > or = 28 days of therapy. Patients receiving primary therapy showed a 61% response versus 56% for the others. The best therapeutic responses were seen for skin/subcutaneous (91%) or bone (79%) infections, and the lowest for CNS infections (43%). Patients without major immune suppression (72%) or those with solid organ transplantation (63%) or various hematological conditions (60%) showed the best responses by underlying condition. Median known survival time was 133 days (therapy successes, 252 days; failures, 21 days). In all, 43 (40%) patients died, 73% due to scedosporiosis. Patients with Scedosporium prolificans infection had significantly reduced survival times (P = 0.0259) and were more likely to die from fungal infection (P = 0.002) than were Scedosporium apiospermum-infected patients. In a subset of 43 patients where voriconazole baseline MICs were available, response to voriconazole was higher for S. apiospermum-infected patients (54% response; MIC(50), 0.25 microg/ml) than for S. prolificans-infected patients (40% response; MIC(50), 4.0 microg/ml). Voriconazole demonstrated clinically useful activity in the treatment of both S. apiospermum and S. prolificans infections and was well tolerated. |
Keywords: | Global Scedosporium Study Group Humans Scedosporium Aspergillosis Triazoles Pyrimidines Antifungal Agents Treatment Outcome Health Surveys Adolescent Adult Aged Aged, 80 and over Middle Aged Child Child, Preschool Infant Female Male Clinical Trials as Topic Voriconazole |
DOI: | 10.1128/AAC.01388-07 |
Published version: | http://dx.doi.org/10.1128/aac.01388-07 |
Appears in Collections: | Aurora harvest 5 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.